PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31885317-0	2020	The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells.	Cisplatin	37-46	AKT serine/threonine kinase 1	Homo sapiens	79-82	
31885317-5	2020	Moreover, a specific small molecule inhibitor of AKT activation, MK2206, effectively reversed the cisplatin resistance in GC caused by CRAL deficiency.	Cisplatin	98-107	AKT serine/threonine kinase 1	Homo sapiens	49-52	
31885317-6	2020	In conclusion, we provide the first evidence that a novel lncRNA, CRAL, could function as a competing endogenous RNA (ceRNA) to reverse GC cisplatin resistance via the miR-505/CYLD/AKT axis, which suggests that CRAL could be considered a potential predictive biomarker and therapeutic target for cisplatin resistance in gastric cancer.	Cisplatin	139-148	AKT serine/threonine kinase 1	Homo sapiens	181-184	
31885317-6	2020	In conclusion, we provide the first evidence that a novel lncRNA, CRAL, could function as a competing endogenous RNA (ceRNA) to reverse GC cisplatin resistance via the miR-505/CYLD/AKT axis, which suggests that CRAL could be considered a potential predictive biomarker and therapeutic target for cisplatin resistance in gastric cancer.	Cisplatin	296-305	AKT serine/threonine kinase 1	Homo sapiens	181-184